The insider sales are routine post-grant liquidity events and not a standalone bearish signal. However, the $400M shelf registration and going-concern warning create acute financing risk. Monitor for an ATM drawdown or equity offering in the coming weeks, which would be highly dilutive. The Phase 3 XPORT-EC-042 endometrial cancer trial enrollment completion is a binary catalyst but does not address near-term cash needs.
Price Chart
Executive Summary
Six Karyopharm executives, including the CEO and C-suite, sold a total of $35K in open-market shares on May 14, 2026, one day after receiving equity grants and one day after the company reported Q1 2026 earnings. The sales are trivial relative to the $201M market cap (0.017%) and coincide with a $400M shelf registration filed 10 days prior, a going-concern warning, and cash runway extending only into late Q3 2026. The cluster is likely liquidity-driven following vesting/grant events rather than a coordinated bearish signal, but the broader capital structure risk is material.
Key Financial Metrics
Key Facts
- Six insiders sold $35K in open-market shares on May 14, 2026, representing 0.017% of market cap
- CEO Richard Paulson sold $21K (2,203 shares at $9.50), the largest sale in the cluster
- All six insiders received equity grants on May 13, 2026 (non-cash, $0 value), followed by sales the next day
- Q1 2026 revenue of $35.1M (up 17% YoY) beat consensus EPS of -$1.44 by 29%, but net loss was $22.4M
- Phase 3 SENTRY myelofibrosis trial missed its second co-primary endpoint (symptom score)
- $400M universal shelf registration (including $100M ATM) filed May 4, representing ~200% of market cap
- Auditor raised substantial doubt about going concern; cash runway extends only into late Q3 2026
- RA Capital shelf registration for 8.8M shares (resale, no proceeds to company) also filed May 4
Financial Impact
Insider sales of $35K are immaterial (0.017% of $201M market cap), but the $400M shelf registration represents potential dilution of ~200% of market cap
Risk Factors
- Massive dilution from $400M shelf registration (200% of market cap) if drawn down
- Cash runway only into late Q3 2026 — likely need for dilutive financing before then
- Phase 3 SENTRY trial missed second co-primary endpoint, raising pipeline uncertainty
- Going-concern warning from auditor signals potential bankruptcy risk without capital infusion
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-KPTI-1778876069336 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 8-K | $1.61 $1.88 | ▼ −16.77% | ▼ −16.99% | $0.8050 (+50.00%) |
Aug 31, 2026 4w ago | 8-K | $2.06 $1.72 | ▼ −16.50% | ▼ −16.36% | $0.8050 (−60.92%) |
Aug 13, 2026 7w ago | 8-K | $1.99 $1.82 | ▲ +8.54% | ▲ +6.58% | $0.8050 (+59.55%) |
Aug 10, 2026 7w ago | Press Release | $1.96 $1.81 | ▼ −7.65% | ▼ −7.61% | $0.8050 (−58.93%) |
Jul 31, 2026 9w ago | 8-K | $1.92 $2.12 | ▲ +10.42% | ▲ +6.91% | $0.8050 (−58.07%) |
Jul 17, 2026 10w ago | 8-K | $7.47 $7.41 | ▼ −0.80% | ▼ −0.38% | $0.8050 (−89.22%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▼ −25.63% | ▼ −24.01% | $0.8050 (+88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access